[Tactics of vaccine prevention of meningococcal infections].
Zh Mikrobiol Epidemiol Immunobiol. 1989.
PMID: 2658434
Review.
Russian.
No abstract available.
Search Page
Filters
Results by year
Table representation of search results timeline featuring number of search results per year.
| Year | Number of Results |
|---|---|
| 1970 | 1 |
| 1976 | 1 |
| 1985 | 1 |
| 1988 | 1 |
| 1990 | 2 |
| 1991 | 4 |
| 1994 | 1 |
| 1995 | 1 |
| 1996 | 3 |
| 1997 | 1 |
| 1998 | 4 |
| 1999 | 2 |
| 2000 | 6 |
| 2001 | 8 |
| 2002 | 4 |
| 2003 | 5 |
| 2004 | 3 |
| 2005 | 9 |
| 2006 | 13 |
| 2007 | 14 |
| 2008 | 8 |
| 2009 | 13 |
| 2010 | 9 |
| 2011 | 6 |
| 2012 | 15 |
| 2013 | 10 |
| 2014 | 13 |
| 2015 | 15 |
| 2016 | 13 |
| 2017 | 13 |
| 2018 | 13 |
| 2019 | 10 |
| 2020 | 18 |
| 2021 | 14 |
| 2022 | 10 |
| 2023 | 7 |
| 2024 | 9 |
| 2025 | 20 |
| 2026 | 5 |
Search Results
274 results
Results by year
Citations
2
articles
found by citation matching
Prevention of meningococcal serogroup B infections in children: a protein-based vaccine induces immunologic memory.
J Infect Dis. 2001.
PMID: 11398116
Clinical Trial.
Search results
Page 1
Doxycycline prophylaxis and meningococcal group B vaccine to prevent bacterial sexually transmitted infections in France (ANRS 174 DOXYVAC): a multicentre, open-label, randomised trial with a 2 2 factorial design.
Lancet Infect Dis. 2024 Oct;24(10):1093-1104. doi: 10.1016/S1473-3099(24)00236-6. Epub 2024 May 23.
Lancet Infect Dis. 2024.
PMID: 38797183
Clinical Trial.
We aimed to assess whether post-exposure prophylaxis (PEP) with doxycycline could reduce the incidence of chlamydia or syphilis (or both) and whether the meningococcal group B vaccine (4CMenB) could reduce the incidence of gonorrhoea in this population. ...The incid …
We aimed to assess whether post-exposure prophylaxis (PEP) with doxycycline could reduce the incidence of chlamydia or syphilis (or both) an …
Effectiveness of MenB-4C Vaccine Against Gonorrhea: A Systematic Review and Meta-analysis.
J Infect Dis. 2025 Feb 4;231(1):61-70. doi: 10.1093/infdis/jiae383.
J Infect Dis. 2025.
PMID: 39082700
Free PMC article.
BACKGROUND: There is no licensed vaccine against gonorrhea, but Neisseria meningitidis serogroup B outer membrane vesicle-based vaccines, such as MenB-4C, may offer cross-protection against gonorrhea. ...RESULTS: Eight articles met our eligibility criteria. Receipt …
BACKGROUND: There is no licensed vaccine against gonorrhea, but Neisseria meningitidis serogroup B outer membrane vesicle-based va …
Efficacy of single-dose HPV vaccination among young African women.
NEJM Evid. 2022 Jun;1(5):EVIDoa2100056. doi: 10.1056/EVIDoa2100056. Epub 2022 Apr 11.
NEJM Evid. 2022.
PMID: 35693874
Free PMC article.
Clinical Trial.
A total of 758 participants received the nonavalent HPV vaccine, 760 received the bivalent HPV vaccine, and 757 received the meningococcal vaccine; retention was 98%. ...Thirty-three incident persistent infections were detected in the HPV 16/18/ …
A total of 758 participants received the nonavalent HPV vaccine, 760 received the bivalent HPV vaccine, and 757 received the …
Vaccine effectiveness and impact of meningococcal vaccines against gonococcal infections: A systematic review and meta-analysis.
J Infect. 2024 Sep;89(3):106225. doi: 10.1016/j.jinf.2024.106225. Epub 2024 Jul 8.
J Infect. 2024.
PMID: 38986746
Free article.
OBJECTIVES: To systematically review and synthesis the evidence of vaccine effectiveness (VE) and impact (VI) of meningococcal vaccines in preventing gonorrhoea. ...CONCLUSIONS: 4CMenB and other MenB-OMV vaccines show moderate effectiveness agai …
OBJECTIVES: To systematically review and synthesis the evidence of vaccine effectiveness (VE) and impact (VI) of meningococcal …
Immunogenicity and safety of the multicomponent meningococcal B vaccine (4CMenB) in children and adolescents: a systematic review and meta-analysis.
Lancet Infect Dis. 2018 Apr;18(4):461-472. doi: 10.1016/S1473-3099(18)30048-3. Epub 2018 Jan 19.
Lancet Infect Dis. 2018.
PMID: 29371070
BACKGROUND: The multicomponent meningococcal serogroup B vaccine (4CMenB) has been licensed in more than 35 countries. However, uncertainties remain about the lowest number of doses required to induce satisfactory, persistent immune responses. We did a systematic re …
BACKGROUND: The multicomponent meningococcal serogroup B vaccine (4CMenB) has been licensed in more than 35 countries. However …
A Phase 3 study to assess the safety and immunogenicity of a quadrivalent meningococcal conjugate vaccine (MenACYW-TT) co-administered with routine pediatric vaccines in healthy infants in the USA and Puerto Rico.
Hum Vaccin Immunother. 2025 Dec;21(1):2588874. doi: 10.1080/21645515.2025.2588874. Epub 2025 Dec 3.
Hum Vaccin Immunother. 2025.
PMID: 41337697
Free PMC article.
Clinical Trial.
A quadrivalent meningococcal tetanus toxoid-conjugate vaccine, MenACYW-TT, has been developed to provide protection against invasive meningococcal disease caused by Neisseria meningitidis serogroups A, C, Y, and W. This Phase 3 study (NCT03537508; April 25, 2 …
A quadrivalent meningococcal tetanus toxoid-conjugate vaccine, MenACYW-TT, has been developed to provide protection against in …
Predictors of meningococcal vaccine uptake in university and college students: a systematic review and meta-analysis.
J Am Coll Health. 2022 Aug-Sep;70(6):1738-1753. doi: 10.1080/07448481.2020.1819292. Epub 2020 Oct 13.
J Am Coll Health. 2022.
PMID: 33048644
Objective: To identify predictors of meningococcal vaccine uptake among university and college students, the most common carriers of meningococcal disease. ...Conclusion: Identified key predictors correspond with previous studies and other vaccines. Th …
Objective: To identify predictors of meningococcal vaccine uptake among university and college students, the most common carri …
Breadth of immune response, immunogenicity, reactogenicity, and safety for a pentavalent meningococcal ABCWY vaccine in healthy adolescents and young adults: results from a phase 3, randomised, controlled observer-blinded trial.
Lancet Infect Dis. 2025 May;25(5):560-573. doi: 10.1016/S1473-3099(24)00667-4. Epub 2024 Dec 5.
Lancet Infect Dis. 2025.
PMID: 39647494
Clinical Trial.
BACKGROUND: A multicomponent meningococcal serogroups ABCWY vaccine (MenABCWY) could provide broad protection against disease-causing meningococcal strains and simplify the immunisation schedule. ...This investigational vaccine could provide broad m …
BACKGROUND: A multicomponent meningococcal serogroups ABCWY vaccine (MenABCWY) could provide broad protection against disease- …
Safety and Immunogenicity of a Quadrivalent Meningococcal Conjugate Vaccine and Commonly Administered Vaccines After Coadministration.
Pediatr Infect Dis J. 2016 Jan;35(1):81-93. doi: 10.1097/INF.0000000000000930.
Pediatr Infect Dis J. 2016.
PMID: 26398743
BACKGROUND: Given the broad age range across which the quadrivalent meningococcal conjugate vaccine MenACWY-CRM is used, coadministration with routine vaccines should be evaluated across age groups for possible immunologic interference and impact on vaccin …
BACKGROUND: Given the broad age range across which the quadrivalent meningococcal conjugate vaccine MenACWY-CRM is used, coadm …
A phase 3, randomized, controlled, open-label study to evaluate the persistence up to 5 years of 1 or 2 doses of meningococcal conjugate vaccine MenACWY-TT given with or without 13-valent pneumococcal conjugate vaccine in 12-14-month-old children.
Vaccine. 2023 Jan 27;41(5):1153-1160. doi: 10.1016/j.vaccine.2022.11.048. Epub 2023 Jan 6.
Vaccine. 2023.
PMID: 36621408
Free article.
Clinical Trial.
BACKGROUND: Immunogenicity and safety up to 5 years after administration of 1 or 2 doses of quadrivalent meningococcal serogroup A, C, W, and Y tetanus toxoid conjugate vaccine (MenACWY-TT) given alone or with 13-valent pneumococcal conjugate vaccine (PCV13) …
BACKGROUND: Immunogenicity and safety up to 5 years after administration of 1 or 2 doses of quadrivalent meningococcal serogroup A, C …
Cite